secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001104659-24-105853
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharma VP Corporate Controller departs; receives base salary through Dec 2024
--------------------------------------------------------------------------------

- Richard Rychlik, VP Corporate Controller, employment ended September 30, 2024.
- Separation agreement provides continued base salary through December 31, 2024.
- Company also subsidizes COBRA premiums through December 31, 2024.
- No successor or replacement officer has been named.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465924105853/0001104659-24-105853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465924105853/tm2425499d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-105853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer